Despite the setbacks, interest in TGF-β remains
Novartis looks set to hand nisevokitug rights back to Xoma, though plenty of work on TGF-β continues.
US approval gives Jemperli a treatment niche
However, endometrial cancer remains a small use, and Jemperli has other ways to make a bigger splash.
